A Phase 1 Trial of FCN-338 in Haematological Malignancies
Latest Information Update: 06 Nov 2020
Price :
$35 *
At a glance
- Drugs FCN-338 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 06 Nov 2020 New trial record
- 29 Oct 2020 According to a Fochon Pharmaceuticals media release, this study is expected to begin in coming months.